Related Experiment Video
Updated: Jul 13, 2026
Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa
Published on: June 30, 2016
High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Pseudomonas aeruginosa is both a model biofilm-forming organism and an opportunistic pathogen responsible for chronic lung infections in cystic fibrosis (CF) patients and infections in burn patients, among other maladies. Here we describe the development of an efficient high-throughput screen to identify small-molecule modulators of biofilm formation. This screen has been run with 66,095 compounds to identify those that prevent biofilm formation without affecting planktonic bacterial growth. The screen is a luminescence-based attachment assay that has been validated with several strains of P. aeruginosa and compared to a well-established but low-throughput crystal violet staining biofilm assay. P. aeruginosa strain PAO1 was selected for use in the screen both because it forms robust biofilms and because genetic information and tools are available for the organism. The attachment-inhibited mutant, strain PAO1 DeltafliC, was used as a screening-positive control. We have also developed and validated a complementary biofilm detachment assay that can be used as an alternative primary screen or secondary screen for the attachment screening-positive compounds. We have determined the potencies of 61 compounds against biofilm attachment and have identified 30 compounds that fall into different structural classes as biofilm attachment inhibitors with 50% effective concentrations of less than 20 microM. These small-molecule inhibitors could lead to the identification of their relevant biofilm targets or potential therapeutics for P. aeruginosa infections.
Insights
Researchers developed a high-throughput screen to find compounds that stop Pseudomonas aeruginosa biofilm formation. This screen identified 30 potential biofilm inhibitors, offering new therapeutic avenues for infections.
Area of Science:
- Microbiology
- Drug Discovery
Background:
- Pseudomonas aeruginosa is a key model organism for biofilm research and an opportunistic pathogen causing infections in cystic fibrosis and burn patients.
- Biofilm formation is crucial for P. aeruginosa pathogenicity and chronic infections, making it a target for therapeutic intervention.
Purpose of the Study:
- To develop and validate a high-throughput screening (HTS) method for identifying small molecules that inhibit P. aeruginosa biofilm formation.
- To identify novel small-molecule inhibitors of P. aeruginosa biofilm attachment.
Main Methods:
- A luminescence-based attachment assay was developed and validated against a crystal violet staining method.
- The HTS was performed using 66,095 compounds, assessing inhibition of biofilm formation without impacting planktonic growth.
- A complementary biofilm detachment assay was also developed and validated.
Main Results:
- The HTS identified 30 compounds that inhibit P. aeruginosa biofilm attachment across diverse structural classes.
- Potency was determined for 61 compounds, with 30 identified as inhibitors having EC50 values below 20 microM.
- The screening method demonstrated efficiency and reliability using P. aeruginosa strain PAO1.
Conclusions:
- The developed HTS is an efficient tool for identifying P. aeruginosa biofilm inhibitors.
- The identified small molecules represent potential leads for developing new therapeutics against P. aeruginosa infections.
- These inhibitors may aid in elucidating the molecular targets involved in P. aeruginosa biofilm development.
